First AD

Second AD

Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.

Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

Video content above is prompted by the following:

What strategies would you implement to mitigate potential adverse events?

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Clinical Advances in Nasopharyngeal Carcinoma

Yale Cancer Center

Cancer Centers

Partner

City of Hope

Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

Current Guidelines for Managing Nasopharyngeal Carcinoma

Overview of the JUPITER and POLARIS-2 Trials

Value of PD-L1 Biomarker in NPC

Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

Clinical Scenario: Locally Recurrent NPC

Clinical Scenario: Metastatic EBV-Positive NPC